OTCMKTS:GNMSF Genmab A/S (GNMSF) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free GNMSF Stock Alerts $279.60 -10.74 (-3.70%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$275.55▼$290.4050-Day Range$275.08▼$313.0052-Week Range$262.00▼$426.50Volume1,217 shsAverage Volume673 shsMarket CapitalizationN/AP/E Ratio29.03Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Genmab A/S alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Genmab A/S Stock (OTCMKTS:GNMSF)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Read More GNMSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNMSF Stock News HeadlinesApril 20, 2024 | americanbankingnews.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average of $301.42April 16, 2024 | seekingalpha.comGenmab Acquires A Missing Piece For Its PipelineApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 16, 2024 | markets.businessinsider.comGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnApril 9, 2024 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Genmab (GMAB)April 8, 2024 | benzinga.comProfoundBio discovers the joys of having a wealthy ownerMarch 17, 2024 | finance.yahoo.com30 Biggest Biotechnology Companies in the WorldMarch 13, 2024 | finance.yahoo.comPassing of Genmab A/S’ Annual General MeetingApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 21, 2024 | seekingalpha.comGenmab: Recent Updates Support The Growth NarrativeFebruary 20, 2024 | markets.businessinsider.com4 Analysts Assess Genmab: What You Need To KnowFebruary 15, 2024 | msn.comGenmab A/S’ New Regulation Risk – A Cause for Worry?February 15, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comNotice to Convene the Annual General Meeting of Genmab A/SFebruary 14, 2024 | finance.yahoo.comGenmab Files Annual Report with the U.S. Securities and Exchange CommissionFebruary 14, 2024 | finance.yahoo.comGenmab: Growth Is Still a Better ChoiceFebruary 2, 2024 | finance.yahoo.comTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerJanuary 29, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For GenmabJanuary 25, 2024 | finance.yahoo.comGrant of Restricted Stock Units and Warrants to Employees in GenmabJanuary 22, 2024 | finance.yahoo.comGenmab Announces Decision in Arbitration Appeal under License Agreement with JanssenDecember 7, 2023 | finance.yahoo.comHRMY or GMAB: Which Is the Better Value Stock Right Now?November 8, 2023 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | msn.comGenmab reports 9M resultsNovember 7, 2023 | finance.yahoo.comGenmab Announces Financial Results for the First Nine Months of 2023November 2, 2023 | finance.yahoo.comGenmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH)October 23, 2023 | msn.comGenmab and Seagen report positive data from Phase III TIVDAK trialOctober 23, 2023 | msn.comSeagen, Genmab update Phase 3 data for uterine cancer therapySee More Headlines Receive GNMSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/14/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:GNMSF CUSIPN/A CIK1434265 Webwww.genmab.com Phone(457) 020-2728Fax45-7020-2729Employees2,204Year Founded1999Profitability EPS (Most Recent Fiscal Year)$9.63 Trailing P/E Ratio29.03 Forward P/E RatioN/A P/E GrowthN/ANet Income$631.91 million Net Margins26.50% Pretax Margin34.22% Return on Equity18.06% Return on Assets16.13% Debt Debt-to-Equity RatioN/A Current Ratio13.34 Quick Ratio13.32 Sales & Book Value Annual Sales$2.39 billion Price / SalesN/A Cash Flow$12.27 per share Price / Cash Flow22.78 Book Value$59.44 per share Price / Book4.70Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.01 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Jan G.J. van de Winkel Ph.D. (Age 63)Co-Founder, President & CEO Comp: $2.88MMr. Anthony Pagano (Age 46)Executive VP & CFO Comp: $1.02MMs. Birgitte Stephensen M.Sc. (Age 63)Executive VP & Chief Legal Officer Comp: $632.67kDr. Martine J. van Vugt Ph.D. (Age 53)Executive VP & Chief Strategy Officer Comp: $690.19kMr. Martin Schultz (Age 48)Senior Director of Clinical Operations & Non-Independent Director Comp: $115.03kDr. Tahamtan Ahmadi (Age 51)Executive VP, Chief Medical Officer & Head of Experimental Medicines Comp: $1.11MDr. Mijke Zachariasse Ph.D. (Age 50)Senior Director, Head of Antibody Research Materials & Non-Independent Director Comp: $158.17kMr. Takahiro Hamatani (Age 49)Senior Director of Finance Japan & Non-Independent Director Comp: $115.03kMr. Anthony Mancini (Age 53)Executive VP & COO Comp: $1.09MMr. Andrew CarlsenSenior Director, VP & Head of Investor RelationsMore ExecutivesKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors GNMSF Stock Analysis - Frequently Asked Questions How have GNMSF shares performed in 2024? Genmab A/S's stock was trading at $315.6999 at the start of the year. Since then, GNMSF stock has decreased by 11.4% and is now trading at $279.60. View the best growth stocks for 2024 here. Are investors shorting Genmab A/S? Genmab A/S saw a increase in short interest in April. As of April 15th, there was short interest totaling 169,700 shares, an increase of 7.3% from the March 31st total of 158,100 shares. Based on an average daily trading volume, of 1,000 shares, the short-interest ratio is presently 169.7 days. View Genmab A/S's Short Interest. How were Genmab A/S's earnings last quarter? Genmab A/S (OTCMKTS:GNMSF) released its earnings results on Wednesday, February, 14th. The company reported $3.63 EPS for the quarter. The business earned $675.29 million during the quarter. Genmab A/S had a net margin of 26.50% and a trailing twelve-month return on equity of 18.06%. How do I buy shares of Genmab A/S? Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNMSF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
